Impact Biomedical Inc
IBO0.511USD
-0.051-9.03%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
6.23MMarket Cap
LossP/E TTM
More Details of Impact Biomedical Inc Company
Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
Impact Biomedical Inc Info
Ticker SymbolIBO
Company nameImpact Biomedical Inc
IPO dateSep 16, 2024
CEOHeuszel (Frank D)
Number of employees2
Security typeOrdinary Share
Fiscal year-endSep 16
Address1400 Broadfield Blvd.
CityHOUSTON
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code77084
Phone15852321500
Websitehttps://www.impactbiomedinc.com/
Ticker SymbolIBO
IPO dateSep 16, 2024
CEOHeuszel (Frank D)
Company Executives of Impact Biomedical Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jason Grady
Mr. Jason Grady
Director
Director
182.00
--
Mr. David K. Keene
Mr. David K. Keene
Independent Director
Independent Director
--
--
Mr. Frank D. Heuszel, CPA
Mr. Frank D. Heuszel, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Christian Zimmerman
Mr. Christian Zimmerman
Independent Director
Independent Director
--
--
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Melissa Sims
Ms. Melissa Sims
Independent Director
Independent Director
--
--
Dr. Elise Brownell
Dr. Elise Brownell
Independent Director
Independent Director
--
--
Mr. Castel B. Hibbert
Mr. Castel B. Hibbert
Independent Director
Independent Director
--
--
Mr. Todd D. Macko
Mr. Todd D. Macko
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Heng Fai (Ambrose) Chan
Mr. Heng Fai (Ambrose) Chan
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jason Grady
Mr. Jason Grady
Director
Director
182.00
--
Mr. David K. Keene
Mr. David K. Keene
Independent Director
Independent Director
--
--
Mr. Frank D. Heuszel, CPA
Mr. Frank D. Heuszel, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Christian Zimmerman
Mr. Christian Zimmerman
Independent Director
Independent Director
--
--
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Melissa Sims
Ms. Melissa Sims
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Chan (Heng Fai Ambrose)
0.34%
BlackRock Institutional Trust Company, N.A.
0.24%
The Vanguard Group, Inc.
0.10%
Heuszel (Frank D.)
0.09%
Two Sigma Investments, LP
0.06%
Other
99.18%
Shareholders
Shareholders
Proportion
Chan (Heng Fai Ambrose)
0.34%
BlackRock Institutional Trust Company, N.A.
0.24%
The Vanguard Group, Inc.
0.10%
Heuszel (Frank D.)
0.09%
Two Sigma Investments, LP
0.06%
Other
99.18%
Shareholder Types
Shareholders
Proportion
Individual Investor
0.43%
Investment Advisor
0.40%
Hedge Fund
0.06%
Investment Advisor/Hedge Fund
0.05%
Corporation
0.02%
Other
99.04%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
25
542.17K
4.45%
+223.27K
2025Q2
27
5.00M
43.10%
+213.82K
2025Q1
27
9.94M
82.23%
+3.86M
2024Q4
21
6.56M
57.06%
+6.27M
2024Q3
14
6.41M
55.73%
+6.41M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Chan (Heng Fai Ambrose)
351.56K
2.88%
-3.92M
-91.76%
Apr 04, 2025
BlackRock Institutional Trust Company, N.A.
252.73K
2.07%
+222.06K
+723.90%
Jun 30, 2025
The Vanguard Group, Inc.
32.44K
0.27%
-94.01K
-74.35%
Jun 30, 2025
Heuszel (Frank D.)
95.47K
0.78%
--
--
Sep 08, 2025
Two Sigma Investments, LP
22.70K
0.19%
+22.70K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
49.87K
0.41%
+26.67K
+114.95%
Jun 30, 2025
Document Security Systems, Inc.
21.26K
0.17%
-161.00K
-88.33%
May 27, 2025
Susquehanna International Group, LLP
30.82K
0.25%
+30.82K
--
Jun 30, 2025
UBS Financial Services, Inc.
39.73K
0.33%
+23.56K
+145.72%
Jun 30, 2025
State Street Investment Management (US)
11.80K
0.1%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Impact Biomedical Inc?
The top five shareholders of Impact Biomedical Inc are:
Chan (Heng Fai Ambrose) holds 351.56K shares, accounting for 2.88% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 252.73K shares, accounting for 2.07% of the total shares.
The Vanguard Group, Inc. holds 32.44K shares, accounting for 0.27% of the total shares.
Heuszel (Frank D.) holds 95.47K shares, accounting for 0.78% of the total shares.
Two Sigma Investments, LP holds 22.70K shares, accounting for 0.19% of the total shares.
Chan (Heng Fai Ambrose) holds 351.56K shares, accounting for 2.88% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 252.73K shares, accounting for 2.07% of the total shares.
The Vanguard Group, Inc. holds 32.44K shares, accounting for 0.27% of the total shares.
Heuszel (Frank D.) holds 95.47K shares, accounting for 0.78% of the total shares.
Two Sigma Investments, LP holds 22.70K shares, accounting for 0.19% of the total shares.
What are the top three shareholder types of Impact Biomedical Inc?
The top three shareholder types of Impact Biomedical Inc are:
Chan (Heng Fai Ambrose)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Chan (Heng Fai Ambrose)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
How many institutions hold shares of Impact Biomedical Inc (IBO)?
As of 2025Q3, 25 institutions hold shares of Impact Biomedical Inc, with a combined market value of approximately 542.17K, accounting for 4.45% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -38.65%.
What is the biggest source of revenue for Impact Biomedical Inc?
In --, the -- business generated the highest revenue for Impact Biomedical Inc, amounting to -- and accounting for --% of total revenue.
